fda compounding semaglutide warning letters november 2025 The has issued to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide June 8, 2026: Reckless physicians

The medication was approved by the FDA in 1959 and remains a short-term appetite suppressant typically used for 12 weeks or less

Therefore, med spas cannot market these treatments using brand names like Ozempic or Wegovy unless they are acquired directly from the manufacturer, Novo Nordisk

On average, people on Semaglutide lose 14.9% of their weight in a year*

Top with berries, chia, and cinnamon

Drinking water with added Himalayan pink salt is being promoted to control weight, but does it work

A NAD-related signal may identify mitochondrial and sirtuin-linked vulnerability, but it must be interpreted with age, inflammation, and renal handling